183 related articles for article (PubMed ID: 12660933)
1. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.
Ackers ML; Parekh B; Evans TG; Berman P; Phillips S; Allen M; McDougal JS
J Infect Dis; 2003 Mar; 187(6):879-86. PubMed ID: 12660933
[TBL] [Abstract][Full Text] [Related]
2. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
4. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
[TBL] [Abstract][Full Text] [Related]
5. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
6. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
[TBL] [Abstract][Full Text] [Related]
8. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
9. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Gilbert PB; Peterson ML; Follmann D; Hudgens MG; Francis DP; Gurwith M; Heyward WL; Jobes DV; Popovic V; Self SG; Sinangil F; Burke D; Berman PW
J Infect Dis; 2005 Mar; 191(5):666-77. PubMed ID: 15688279
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
[TBL] [Abstract][Full Text] [Related]
11. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
12. Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
[TBL] [Abstract][Full Text] [Related]
14. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
Goepfert PA; Horton H; McElrath MJ; Gurunathan S; Ferrari G; Tomaras GD; Montefiori DC; Allen M; Chiu YL; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Keefer MC; Baden LR; Corey L;
J Infect Dis; 2005 Oct; 192(7):1249-59. PubMed ID: 16136469
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
Pitisuttithum P; Nitayaphan S; Thongcharoen P; Khamboonruang C; Kim J; de Souza M; Chuenchitra T; Garner RP; Thapinta D; Polonis V; Ratto-Kim S; Chanbancherd P; Chiu J; Birx DL; Duliege AM; McNeil JG; Brown AE;
J Infect Dis; 2003 Jul; 188(2):219-27. PubMed ID: 12854076
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
Khurana S; Needham J; Mathieson B; Rodriguez-Chavez IR; Catanzaro AT; Bailer RT; Kim J; Polonis V; Cooper DA; Guerin J; Peterson ML; Gurwith M; Nguyen N; Graham BS; Golding H
J Virol; 2006 Mar; 80(5):2092-9. PubMed ID: 16474117
[TBL] [Abstract][Full Text] [Related]
17. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
Borkowsky W; Wara D; Fenton T; McNamara J; Kang M; Mofenson L; McFarland E; Cunningham C; Duliege AM; Francis D; Bryson Y; Burchett S; Spector SA; Frenkel LM; Starr S; Van Dyke R; Jimenez E
J Infect Dis; 2000 Mar; 181(3):890-6. PubMed ID: 10720509
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
McFarland EJ; Borkowsky W; Fenton T; Wara D; McNamara J; Samson P; Kang M; Mofenson L; Cunningham C; Duliege AM; Sinangil F; Spector SA; Jimenez E; Bryson Y; Burchett S; Frenkel LM; Yogev R; Gigliotti F; Luzuriaga K; Livingston RA;
J Infect Dis; 2001 Nov; 184(10):1331-5. PubMed ID: 11679925
[TBL] [Abstract][Full Text] [Related]
19. [HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis].
Chen Y; Garcia R; Baralle FE
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Apr; 19(2):120-6. PubMed ID: 10453506
[TBL] [Abstract][Full Text] [Related]
20. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.
Stambas J; Brown SA; Gutierrez A; Sealy R; Yue W; Jones B; Lockey TD; Zirkel A; Freiden P; Brown B; Surman S; Coleclough C; Slobod KS; Doherty PC; Hurwitz JL
Vaccine; 2005 Mar; 23(19):2454-64. PubMed ID: 15752831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
